4Portoles J,Lopez-Gomez JM,Aljama P.On behalf of the MAR Study Group.A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients:the MAR Study.Neohrol Dial Transplant,2007,22:500-507.
5Lecatelli F,Pisoni RL,Combe C,et al.Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).Nephrol Dial Transplant,2004,19:121-132.
6Vanwyck DB,Danielson BG,Aronoff GR.Making sense:A scientific approach to intravenous iron therapy.J Am Soc Nephrol,2004,15:91-92.
7Danielson BG.Structure,chemistry,and pharmaeokineties of intravenous iron agents.J Am Soc Nephrol,2004,15:93-98.
8Aronoff GR.Safety of intravenous iron in clinical practice:implications for anemia management protocols.J Am Soc Nephrol,2004,15:99-106.
9VanWyck DB.Labile iron:manifestations and clinical implications.J Am Soc Nephrol,2004,15:107-111.
10EschbachJW,EgrieJC,DowningMR.Correctionoftheanemiaofend-stagerenaldiseasewithrecombinanthumanerythropoietin[].The New England Journal of Medicine.1987
